CompletedPHASE1, PHASE2NCT02132624

CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.

Studying B-cell chronic lymphocytic leukemia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Uppsala University
Principal Investigator
Angelica Loskog, PhD, M.D., PhD
Uppsala University
Intervention
Autologous 3rd generation CD19-targeting CAR T cells(biological)
Enrollment
15 enrolled
Eligibility
18 years · All sexes
Timeline
2014 – 2017

Study locations (1)

Collaborators

Uppsala University Hospital · Karolinska University Hospital · AFA Insurance · Swedish Cancer Society

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02132624 on ClinicalTrials.gov

Other trials for B-cell chronic lymphocytic leukemia

Additional recruiting or active studies for the same condition.

See all trials for B-cell chronic lymphocytic leukemia →

← Back to all trials